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RESPONSE
Evidence for light-entrainment-induced switching between
depression- & mania-relevant behaviors in mice
Neuropsychopharmacology (2019) 0:1–2; https://doi.org/10.1038/s41386-019-0338-3
We appreciate Rosenthal and McCarty’s careful read of our study
[1], demonstrating that mice kept in short- and long-active (SA
and LA respectively) photoperiods (19Light;5Dark, 5Light:19Dark
respectively), exhibit neurotransmitter and behavioral switching.
The mice with reduced dopamine transporters (DAT) exhibit a
hypersensitivity to these photoperiods, recreates common obser-
vations in bipolar disorder (BD), AKA seasonality, with mania
observed in patients as they enter LA (summer), and depression in
patients as they enter SA (winter) photoperiods. Given that
unmedicated BD patients exhibit lower expression of DAT, this
work highlights seasonality as perhaps the origin of/contributor to
switching between states in BD. The authors’ commentary raises 3
concerns regarding such an interpretation. We appreciate the
opportunity and space here to provide clarity.
Concern 1: C57BL/6J mice do not possess melatonin, hence why
would they exhibit different behaviors with shifted photoperiods?
C57BL/6 mice clearly exhibit shifts in behavior with changing
photoperiods, both in our and others’ studies [2]. This premise is
supported by ﬁndings that “melatonin is not required to initiate or
even maintain circadian rhythms” [3]. The superchiasmatic nucleus
(SCN) is the brain region where light information is ﬁrst processed.
The SCN stores photoperiodic information by producing an
electrical activity waveform, triggering behavioral activity (offset
at >50%, onset at <50%; [4]. Peak activity of the SCN’s electrical
activity pattern is compressed in a SA photoperiod, but dilated for
LA photoperiods [5]. We observed neurotransmitter switching in
the paraventricular nuclei (PVN), with somatostatin (SST) expressed
during SA and tyrosine hydroxylase (TH) expressed during LA
photoperiods consistent with rats [6]. The PVN is the next structure
relaying light information and the SCN-PVN axis is essential for
relaying photoperiodic information to other parts of the body, with
PVN volume ﬂuctuating seasonally [7], unlike other brain regions.
Further, removing the pineal gland – source of melatonin – exerts
only limited effects on mammalian circadian rhythmicity [8].
Hence, the concern that lack of melatonin may invalidate our
interpretations is inconsistent with current understanding of
photoperiodic entrainment. We suggest the mechanism under-
lying changes in our observations are not melatonin-dependent.
Interestingly, and in support of our overall interpretation for BD, a
meta-analysis of melatonin studies reveal no utility as a treatment
for BD [9], despite light exposure being useful [10].
Concern 2: The change in photoperiod length was insufﬁcient
for mice to entrain behaviorally and neurophysiologically, citing a
‘need’ for 30 days for ‘consistent’ waveform changes in the
circadian rhythm. Our study did not investigate consistency, but
the transition to altered photoperiods. It is the transition to winter
or summer that seems to affect people with BD more, rather than
their prolonged presence, a separation we intend to explore
further. The fact that the same behaviors and neurotransmitter
switching seen in our publication (immobility/open arm entries
and TH/SST balance) replicated 7 days of entrainment in rats [6] –
roughly the timeline needed for human photoperiodic entrain-
ment – strongly supports this cross-species phenomenon.
Concern 3: use of nomenclature. We utilized SA and LA because
it represents the activity time of the animal, since the mice are
nocturnal it appeared the simplest way to convey consistency
with other diurnal organisms, especially with changes in activity as
occurs in seasonal photoperiods in humans even with electric
lighting. Given the primary concern of the work was an attempt to
explain observations in human BD phenomenon, we felt it best to
create cross-species consistent nomenclature, as our laboratory
and others continually strive toward (e.g., testing nocturnal
animals only in their dark (active) photoperiod vs. light period
just because humans are tested in the light). Certainly, it offers an
opportunity for consistency across species as opposed to the
confusion of delineating nocturnal/diurnal comparisons. We
appreciate the concern raised, however, as it provides further
opportunity to explain our reasoning.
In summary, we appreciate the attention the authors brought to
our study, the concerns raised provided greater opportunity to
delineate our approach. We hope this response goes a way toward
clarifying that approach.
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